Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Effect of obesity on the pharmacokinetics of drugs in humans.

Hanley MJ, Abernethy DR, Greenblatt DJ.

Clin Pharmacokinet. 2010;49(2):71-87. doi: 10.2165/11318100-000000000-00000. Review.

PMID:
20067334
2.

Effects of obesity on pharmacokinetics implications for drug therapy.

Cheymol G.

Clin Pharmacokinet. 2000 Sep;39(3):215-31. Review.

PMID:
11020136
3.

Clinical pharmacokinetics of drugs in obesity. An update.

Cheymol G.

Clin Pharmacokinet. 1993 Aug;25(2):103-14. Review.

PMID:
8403734
4.

What is the best size descriptor to use for pharmacokinetic studies in the obese?

Green B, Duffull SB.

Br J Clin Pharmacol. 2004 Aug;58(2):119-33. Review.

5.

Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.

Ghobadi C, Johnson TN, Aarabi M, Almond LM, Allabi AC, Rowland-Yeo K, Jamei M, Rostami-Hodjegan A.

Clin Pharmacokinet. 2011 Dec 1;50(12):809-22. doi: 10.2165/11594420-000000000-00000.

PMID:
22087867
6.

Lean body mass as a predictor of drug dosage. Implications for drug therapy.

Morgan DJ, Bray KM.

Clin Pharmacokinet. 1994 Apr;26(4):292-307. Review.

PMID:
8013162
7.

Dosing dilemmas in obese children.

Mulla H, Johnson TN.

Arch Dis Child Educ Pract Ed. 2010 Aug;95(4):112-7. doi: 10.1136/adc.2009.163055. Review.

PMID:
20585055
8.

Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics.

Bearden DT, Rodvold KA.

Clin Pharmacokinet. 2000 May;38(5):415-26. Review.

PMID:
10843460
9.

Drug disposition in obesity and protein-energy malnutrition.

Boullata JI.

Proc Nutr Soc. 2010 Nov;69(4):543-50. doi: 10.1017/S0029665110001990. Review.

PMID:
20696092
10.

The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.

McLeay SC, Morrish GA, Kirkpatrick CM, Green B.

Clin Pharmacokinet. 2012 May 1;51(5):319-30. doi: 10.2165/11598930-000000000-00000. Review.

PMID:
22439649
11.

Drug pharmacokinetics in the obese.

Cheymol G.

Fundam Clin Pharmacol. 1988;2(3):239-56. Review.

PMID:
3042569
12.

Influence of obesity on drug disposition.

Blouin RA, Kolpek JH, Mann HJ.

Clin Pharm. 1987 Sep;6(9):706-14. Review.

PMID:
3315402
13.

The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.

Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J.

Clin Pharmacokinet. 2011 Feb;50(2):99-110. doi: 10.2165/11539220-000000000-00000. Review.

PMID:
21142293
14.

The effect of body weight on dalteparin pharmacokinetics. A preliminary study.

Yee JY, Duffull SB.

Eur J Clin Pharmacol. 2000 Jul;56(4):293-7.

PMID:
10954342
15.

Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder.

Lobo ED, Quinlan T, Prakash A.

Clin Pharmacokinet. 2014 Aug;53(8):731-40. doi: 10.1007/s40262-014-0149-y.

PMID:
24989060
17.

Drug disposition in obese humans. An update.

Abernethy DR, Greenblatt DJ.

Clin Pharmacokinet. 1986 May-Jun;11(3):199-213. Review.

PMID:
3524955
18.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
19.

The impact of obesity and disease on busulfan oral clearance in adults.

Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR, Slattery JT.

Blood. 1999 Jun 15;93(12):4436-40.

20.

[Pharmacokinetic changes in obesity].

Girardin E, Bruguerolle B.

Therapie. 1993 Jul-Aug;48(4):397-402. French.

PMID:
8128423
Items per page

Supplemental Content

Support Center